Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

Intelligence powered by the Humanexa engine.

Regeneron — PDUFA Date: Dupixent | Humanexa Signals | Humanexa Signals

Catalyst

Regeneron — PDUFA Date: Dupixent

Regeneron — PDUFA Date — Dupixent in Chronic obstructive pulmonary disease.

Strategic implication

COPD label expansion would open multi-billion TAM beyond atopic indications.

Date

June 27, 2026

Phase

NDA/BLA

Status

confirmed

Signal score

8.3

Newsletter

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.